Autophagy is a conserved cellular degradation and recycling process in the lysosome.There are three main types of autophagy in mammalian cells: macroautophagy, chaperone-mediated autophagy (CMA), and microautophagy. While CMA uses chaperones to identify cargo proteins and then unfolds and transfers them into the lysosome, macroautophagy sequesters cargo by autophagosomes—de novo synthesized of double-membrane vesicles—and then transports it to the lysosome. Microphagy captures cargoes by means of invaginations or protrusions of the lysosomal membrane directly.
The most well-studied form of autophagy, macroautophagy, is low-level and occurs by default. However, under stress conditions, such as nutrient or energy deprivation, it can also be further induced. The ubiquitin-proteasome system (UPS), a crucial protein degradation pathway, collaborates with stress-induced macrophagy to play a significant role in protein catabolism.
As the research went on, it was discovered that autophagy plays a crucial role in the catabolism of a variety of cellular components, including protein aggregates (aggrephagy), lipid droplets (lipophagy), iron complexes (Ferritinophagy), and carbohydrates. Except for macromolecules, autophagy can also target several organelles and structures, such as mitochondria (mitophagy), peroxisome (pexophagy), endoplasmic reticulum (reticulophagy or ER-phagy), ribosome (ribophagy), spermatozoon-inherited organelles following fertilization (allophagy), secretory granules within pancreatic cells (zymophagy) and intracellular pathogens (xenophagy).
Numerous human pathologies, such as aging, cancer, neurodegenerative disease, heart disease, and metabolic diseases like diabetes, are linked to autophagy and its dysfunction. Numerous prescription medications and herbal remedies affect autophagy through various signaling pathways. Small molecules that control autophagy appear to have a great deal of promise for treating these diseases in animal models or in clinical settings.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1381 | NICLOSAMIDE (BAY2353) | 50-65-7 | Niclosamide(Clonitralide, Fenasal, BAY-2353, NSC-178296, WR-46234) is a potent and orally bioavailable chlorinated salicylanilide analog with anthelmintic and potential antineoplastic activity. |
|
V56529 | Nifedipine-d4 (BAY-a-1040-d4) | 1219798-99-8 | Nifedipine-d4 is the deuterium labelled form of Nifedipine. |
|
V56535 | Nilotinib-d3 | 1215678-43-5 | Nilotinib-d3 is the deuterium labelled form of Nilotinib. |
|
V1316 | NIMODIPINE (BAY-e 9736) | 66085-59-4 | Nimodipine (formerly BAY E 9736;BAY-E-9736, Nimotop, Periplum)is a potent dihydropyridine/DHP class of calcium channel blocker (CCB) and an autophagy inhibitor with antihypertensive effects. |
|
V56511 | Nimodipine-d7 (nimodipine d7) | 1246815-36-0 | Nimodipine-d7 is the deuterium labelled form of Nimodipine. |
|
V52793 | Nitrendipine-d5 (AY-E-5009-d5) | 2469554-26-3 | Nitrendipine-d5 is the deuterium labelled form of Nitrendipine. |
|
V41100 | Norswertianin | 22172-15-2 | Norswertianin is a xanthone compound and a potent anti-glioma compound. |
|
V5015 | NSC 185058 | 39122-38-8 | NSC 185058 (NSC-185058) is an inhibitor of ATG4B which is a major cysteine protease, and inhibition of ATG4B by NSC185058 markedly attenuates autophagic activity. |
|
V56516 | Obeticholic acid-d5 (INT-747-d5; 6-ECDCA-d5; 6-Ethylchenodeoxycholic acid-d5) | 1992000-80-2 | Obeticholic acid-d5 is the deuterated form of Obeticholic acid. |
|
V56472 | Olaparib-d4-1 (AZD2281-d4-1; KU0059436-d4-1) | 2143107-55-3 | Olaparib-d4-1 is the deuterated form of Olaparib. |
|
V56239 | Omeprazole-13C,d3 (H 16868-13C,d3) | 1261395-28-1 | Omeprazole-13C,d3 is a 13C (carbon 13)-labeled and deuterated Omeprazole. |
|
V56254 | Omeprazole-d3-1 (H 16868-d3-1) | 934293-92-2 | Omeprazole-d3-1 is the deuterated form of Omeprazole. |
|
V56478 | Paeonol-d3 | 55712-78-2 | Paeonol-d3 is deuterated Paeonol. |
|
V56536 | pamapimod-d4 | 1246814-57-2 | Pamapimod-d4 is the deuterium labelled form of Pamapimod. |
|
V56517 | Pazopanib-13C,d3 (GW786034-13C,d3) | 1261734-88-6 | Pazopanib-13C,d3 is the deuterated form of 13C (carbon 13)-labeled Pazopanib. |
|
V56525 | Pazopanib-13C,d3 hydrochloride (GW786034-13C,d3 hydrochloride) | 1261398-44-0 | Pazopanib-13C,d3 ( HCl) is a multi-target inhibitor, inhibiting VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140, and 146 respectively. |
|
V56501 | Pazopanib-d6 (GW786034-d6) | 1219592-01-4 | Pazopanib-d6 is the deuterated form of Pazopanib. |
|
V32203 | Peiminine | 18059-10-4 | Peiminine is a compound extracted from Bolbostemma paniculatum (Maxim) Franquet of the squash family. |
|
V56490 | Pemetrexed-d5 (LY231514-d5) | 1129408-57-6 | Pemetrexed-d5 is the deuterium labelled form of Pemetrexed. |
|
V52780 | Pentoxifylline-d5 (BL-191-d5; PTX-d5; Oxpentifylline-d5) | 1185995-18-9 | Pentoxifylline-d5 is the deuterium labelled form of Pentoxifylline. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
